Menu
ncarol.com
  • Home
  • Business
  • Financial
  • Banking
  • Finance
  • Nyse
  • Stocks
  • Yacht Buyer
  • Loans
ncarol.com

Isosceles Pharmaceuticals, Inc. Appoints William D. Humphries as its Chief Executive Officer
ncarol.com/10114932

Trending...
  • François Arnaud, star of Heated Rivalry, is the real-life inspiration behind Christopher Stoddard's novel At Night Only
  • Caraline Skincare's Gentle Glow Cleansing Oil Named Finalist for Best Face Cleanser at the 2026 CertClean Clean Beauty Awards​
  • Ice Melts. Infrastructure Fails. What Happens to Clean Water?
WILMINGTON, N.C., May 5, 2021 /PRNewswire/ -- Isosceles Pharmaceuticals Inc. a biotechnology company dedicated to developing, commercializing, and marketing innovative non-opioid products for the treatment of mild to moderate pain and inflammatory diseases, today announced the appointment of William D. Humphries as its Chief Executive Officer. Mr. Humphries is a highly accomplished executive leader in the pharmaceutical industry with a proven track record leading several global pharmaceutical companies.

"We are excited to welcome Bill for the role of Chief Executive Officer," said Tim Wright, Chairman of Isosceles Board of Directors. "His extensive background in the pharmaceutical industry will provide invaluable leadership as Isosceles achieves its strategic growth milestones."

Most recently, Mr. Humphries served as President of Ortho Dermatologics, a subsidiary of  Bausch Health Companies. He has also held global executive leadership positions at Merz North America, GlaxoSmithKline, Stiefel, and Allergan.

"I would like to thank Tim and the Isosceles team for welcoming me to company," said Mr. Humphries, Chief Executive Officer of Isosceles. "I was attracted to Isosceles by their focus on the pursuit of innovative solutions for safe, novel non-opioid pain relief and the passion the team has for delivering these important products to the market. I look forward to leveraging my experience to accelerate the company's development plans and lead Isosceles as it unlocks its full potential."

More on ncarol.com
  • Amicly Launches as a Safety-First Social App Designed to Help People Build Real, Meaningful Friendships
  • Primeindexer Google indexing platform launched by SEO Danmark APS
  • Kaltra Introduces New Downward-Spraying Distribution Technology to Boost Microchannel Evaporator Performance
  • Talentica Announces Winners of Multi-Agent Hackathon 2026
  • Special Alert: Undervalued Opportunity: IQSTEL (N A S D A Q: IQST) Positioned for Explosive Multi-Year Growth

Mr. Humphries currently serves as Chairman of the Board at Clearside Biomedical, Chairman of the North Carolina State University Global Luxury Management Board, is a member of the Board at Aclaris Therapeutics, and a member of the Board at Strata Skin Sciences. He received his MBA from Pepperdine University and completed his undergraduate studies at Bucknell University.

About Isosceles Pharmaceuticals, Inc.

Isosceles Pharmaceuticals is a preclinical stage biotechnology and medical device company focused on the delivery of drug master file backed synthetic cannabinoids for their anti-inflammatory and pain relief properties. The Company's proprietary formulations coupled with unique delivery platforms provide high bioavailability via parenteral and transdermal routes.

Investor Contact
Brett Lanier
[email protected]

SOURCE Isosceles Pharmaceuticals, Inc.

Related Links

www.isoscelespharma.com
Filed Under: Business

Show All News | Report Violation

0 Comments
1000 characters max.

Latest on ncarol.com
  • Husband and Wife Release Children's Book and Donate Proceeds to Non-Profit
  • Ludex Partners With Certified Trading Card Association (CTCA) To Elevate Standards And Innovation In The Trading Card Industry
  • Best Book Publishing Company for Aspiring Authors
  • Dr. Nadene Rose Releases Moving Memoir on Faith, Grief, and Divine Presence
  • Gigasoft Solves AI's Biggest Charting Code Problem: Hallucinated Property Names
  • AKG To Demonstrate New Digital E-catalog Experience Daily At CONEXPO CON/AGG 2026
  • ASTI Ignites the Space Economy: Powering SpaceX's NOVI AI Pathfinder with Breakthrough Solar Technology: Ascent Solar Technologies (N A S D A Q: ASTI)
  • STEM For Kids Launches Root Protocol™: A Human Bridge for Gen Alpha's Digital Curiosity Crisis
  • Hiring has reached a "Digital Stalemate"—Now, an ex-Google recruiter is giving candidates the answers
  • 2026 Pre-Season Testing Confirms a Two-Tier Grid as Energy Management Defines Formula 1's New Era
  • Platinum Car Audio LLC Focuses on Customer-Driven Vehicle Audio and Electronics Solutions
  • Postmortem Pathology Expands Independent Autopsy Services in Kansas City
  • Postmortem Pathology Expands Independent Autopsy Services Across Colorado
  • $38 Million in U.S. Government Contract Awards Secured Through Strategic Partner. Establishing Multi-Year Defense Revenue Platform Through 2032: $BLIS
  • Mecpow M1: A Safe & Affordable Laser Engraver Built for Home DIY Beginners
  • CrashStory.com Launches First Colorado Crash Data Platform Built for Victims, Not Lawyers
  • Inkdnylon Earns BBB Accreditation for Verified Business Integrity
  • Josh Stout "The Western Project"
  • Open House Momentum Builds at Heritage at South Brunswick
  • A Celebration of Visibility, Voice and Excellence: The 57th NAACP Image Awards Golf Invitational, Presented by Wells Fargo, A PGD Global Production
_catLbl0 _catLbl1

Popular on ncarol.com

  • Finland's €1.3 Billion Digital Gambling Market Faces Regulatory Tug-of-War as Player Protection Debate Intensifies - 109
  • Desert Mountain Club Earns Prestigious Blue Zones Approved™ Triple Designation, a New Standard for Well-Being in a Luxury Lifestyle Community - 108
  • Postmortem Pathology Expands to Phoenix: Bringing Families Answers During Their Most Difficult Moments
  • HELM Audio™ Partners with PQCrypto to Future-Proof Children's Hearing and Safety Data Using Post-Quantum Cryptography
  • CNCPW Divulga Dados de Liquidez do 1º Trimestre: Confirma 100% de Reservas e Atualiza Protocolos de "Saque CNCPW" Contra Fluxos Ilícitos
  • Blasting Off with Space Sector Companies: Artemis II Manned Moon Mission is Set to Launch: Could $ASTI be on the Same Rocket Ride as $ASTS & $LUNR?
  • purelyIV Expands Concierge Wellness Platform with New IV Therapies, Memberships, and Digital Experience
  • Still Using Ice? FrostSkin Reinvents Hydration
  • CCHR: Europe Rejects Forced Psychiatry—Landmark Vote Declares Coercive Practices Incompatible with Human Rights
  • Wall Street Is Missing This One: Cycurion (NAS DAQ: CYCU) Gets $7 Price Target While Trading at a Steep Discount

Similar on ncarol.com

  • VENUS Goes Live on CATEX Exchange As UK Financial Ltd Activates The Premier Division Of The Maya Meme's League
  • Atlanta Tech Founder Seeks Clarity on Intellectual Property and Innovation Policy
  • Special Alert: Undervalued Opportunity: IQSTEL (N A S D A Q: IQST) Positioned for Explosive Multi-Year Growth
  • Triple-Digit Growth, Strategic N A S D A Q Uplist, Plus A Scalable Healthcare Rollout Model: Stock Symbol: CDIX
  • 66% of US Bankruptcies Are Medical — So Americans Are Building Businesses That Cover Healthcare Emergencies
  • Ludex Partners With Certified Trading Card Association (CTCA) To Elevate Standards And Innovation In The Trading Card Industry
  • ASTI Ignites the Space Economy: Powering SpaceX's NOVI AI Pathfinder with Breakthrough Solar Technology: Ascent Solar Technologies (N A S D A Q: ASTI)
  • Hiring has reached a "Digital Stalemate"—Now, an ex-Google recruiter is giving candidates the answers
  • Platinum Car Audio LLC Focuses on Customer-Driven Vehicle Audio and Electronics Solutions
  • Postmortem Pathology Expands Independent Autopsy Services in Kansas City
Copyright © 2026 ncarol.com | Contact Us | Privacy Policy | Terms of Service | Contribute